The relationship between triglyceride levels and medication overuse headache in patients with chronic migraine

Background: Emerging evidence suggests that disturbances in lipid metabolism play a significant role in the etiology of migraines. However, the relationship between lipid metabolism disturbances and medication overuse headache (MOH) remains uncertain. This study aims to evaluate the association between elevated triglyceride (TG) levels and the occurrence of MOH among patients with chronic migraine (CM). Methods: A total of 267 hospitalized individuals diagnosed with CM were enrolled into the study. The participants were divided into two distinct groups based on the presence or absence of MOH. Questionnaires were employed for gathering demographic data, and a systematic inquiry was conducted to ascertain the overall prevalence of headaches. The laboratory examination, anxiety and depression scale, Pittsburgh sleep quality index, and other components were used to evaluate improvement. Initially, the study data underwent univariate analysis, whereby indicators demonstrating statistical significance (p < 0.05) were chosen as independent variables. Subsequently, a binary logistic regression analysis was conducted. Results: The cohort included a total of 87 patients without MOH and 180 patients with MOH. The following five risk variables emerged via single-factor analysis (p < 0.05): headache duration (years), headache frequency (days/months), headache intensity measured by a visual analogue scale (0–10), diabetes history, and TG levels. Elevated TG was associated with greater odds (OR = 1.498 (1.018, 2.259), p = 0.037) of MOH after accounting for demographics, headache features, and cardiometabolic comorbidities (including diabetes and hypertension). Conclusions: Elevated TG levels may be associated with MOH in patients with CM, underscoring their importance in the diagnostic evaluation and therapeutic management of patients with CM.

Medication overuse headache; Chronic migraine; Dyslipidemia

[1] GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392: 1923–1994.

[2] Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018; 38: 1–211.

[3] Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurologic Clinics. 2019; 37: 631–649.

[4] Park HK, Cho SJ. Medication-overuse headache: diagnostic criteria, epidemiology, and treatment. Journal of the Korean Neurological Association. 2023; 41: 1–10.

[5] Jao CW, Wu YT, Chen WH, Yeh JH, Tsai YF, Hsiao CY, et al. Brain structural network modular and connectivity alterations in subtypes of patients with migraine and medication overuse headache. Progress in Brain Research. 2024; 290: 23–61.

[6] Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. The Lancet Neurology. 2010; 9: 391–401.

[7] Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. The Journal of Headache and Pain. 2018; 19: 50.

[8] Burch R. Chronic migraine in adults. JAMA. 2025; 333: 423–424.

[9] Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014; 34: 409–425.

[10] Zhuang C, Mao J, Ye H, He J, Hu Y, Hu H, et al. Association between severe headache or migraine and lipid accumulation product and visceral adiposity index in adults: a cross-sectional study from NHANES. Lipids in Health and Disease. 2024; 23: 307.

[11] Uygur-Kucukseymen E, Akca G. Serum lipid profile in migraine and its association with clinical characteristics. Neurological Research. 2023; 45: 57–61.

[12] Yan Z, Duan L, Yin H, Wang M, Li J, Li C, et al. The value of triglyceride-glucose index-related indices in evaluating migraine: perspectives from multi-centre cross-sectional studies and machine learning models. Lipids in Health and Disease. 2025; 24: 230.

[13] Al-Hassany L, van Drie RWA, Boucherie DM, MaassenVanDenBrink A. Unraveling the paradox: cardiovascular risk profiling in migraine—a correspondence. The Journal of Headache and Pain. 2025; 26: 113.

[14] Tietjen G. Migraine as a systemic vasculopathy. Cephalalgia. 2009; 29: 989–996.

[15] Siewert KM, Klarin D, Damrauer SM, Chang KM, Tsao PS, Assimes TL, et al. Cross-trait analyses with migraine reveal widespread pleiotropy and suggest a vascular component to migraine headache. International Journal of Epidemiology. 2020; 49: 1022–1031.

[16] Guo Y, Daghlas I, Gormley P, Giulianini F, Ridker PM, Mora S, et al. Phenotypic and genotypic associations between migraine and lipoprotein subfractions. Neurology. 2021; 97: e2223–e2235.

[17] Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, Löf E, et al. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. Journal of Neurology. 2023; 270: 5692–5710.

[18] Koonalintip P, Phillips K, Wakerley BR. Medication-overuse headache: update on management. Life. 2024; 14: 1146.

[19] García-Pérez-de-Sevilla G, González-de-la-Flor Á. Impact of fatty acid supplementation on migraine outcomes: a systematic review and meta-analysis. Nutrition Reviews. 2025; 83: 1621–1630.

[20] Wang HF, Liu WC, Zailani H, Yang CC, Chen TB, Chang CM, et al. A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain, Behavior, and Immunity. 2024; 118: 459–467.

[21] Tseng PT, Zeng BY, Chen JJ, Kuo CH, Zeng BS, Kuo JS, et al. High dosage omega-3 fatty acids outperform existing pharmacological options for migraine prophylaxis: a network meta-analysis. Advances in Nutrition. 2024; 15: 100163.

[22] Chen TB, Yang CC, Tsai IJ, Yang HW, Hsu YC, Chang CM, et al. Neuroimmunological effects of omega-3 fatty acids on migraine: a review. Frontiers in Neurology. 2024; 15: 1366372.

[23] Castor K, Dawlaty J, Arakaki X, Gross N, Woldeamanuel YW, Harrington MG, et al. Plasma lipolysis and changes in plasma and cerebrospinal fluid signaling lipids reveal abnormal lipid metabolism in chronic migraine. Frontiers in Molecular Neuroscience. 2021; 14: 691733.

[24] Sanders AE, Weatherspoon ED, Ehrmann BM, Soma PS, Shaikh SR, Preisser JS, et al. Circulating omega-6 and omega-3 polyunsaturated fatty acids in painful temporomandibular disorder and low back pain. The Journal of Pain. 2022; 23: 1724–1736.

[25] Jakobsson JE, Menezes J, Krock E, Hunt MA, Carlsson H, Vaivade A, et al. Fibromyalgia patients have altered lipid concentrations associated with disease symptom severity and anti-satellite glial cell IgG antibodies. The Journal of Pain. 2025; 29: 105331.

[26] Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain. 2012; 153: 56–61.

[27] Saylor D, Steiner T. The global burden of headache. Seminars in Neurology. 2018; 38: 182–190.

[28] He Z, Dong L, Zhang Y, Kong Q, Tan G, Zhou J. Metabolic syndrome in female migraine patients is associated with medication overuse headache: a clinic-based study in China. European Journal of Neurology. 2015; 22: 1228–1234.

[29] Togha M, Karimitafti MJ, Ghorbani Z, Farham F, Naderi-Behdani F, Nasergivehchi S, et al. Characteristics and comorbidities of headache in patients over 50 years of age: a cross-sectional study. BMC Geriatrics. 2022; 22: 313.

[30] Sancisi E, Cevoli S, Vignatelli L, Nicodemo M, Pierangeli G, Zanigni S, et al. Increased prevalence of sleep disorders in chronic headache: a case-control study. Headache. 2010; 50: 1464–1472.

[31] Rivera-Mancilla E, Al-Hassany L, Villalón CM, MaassenVanDenBrink A. Metabolic aspects of migraine: association with obesity and diabetes mellitus. Frontiers in Neurology. 2021; 12: 686398.

[32] Peterlin BL, Sacco S, Bernecker C, Scher AI. Adipokines and migraine: a systematic review. Headache. 2016; 56: 622–644.

[33] Paolucci M, Altamura C, Vernieri F. The role of endothelial dysfunction in the pathophysiology and cerebrovascular effects of migraine: a narrative review. Journal of Clinical Neurology. 2021; 17: 164–175.

[34] Gosalia H, Moreno-Ajona D, Goadsby PJ. Medication-overuse headache: a narrative review. The Journal of Headache and Pain. 2024; 25: 89.

[35] Rosignoli C, Ornello R, Onofri A, Caponnetto V, Grazzi L, Raggi A, et al. Applying a biopsychosocial model to migraine: rationale and clinical implications. The Journal of Headache and Pain. 2022; 23: 100.

[36] Da Silva AN, Lake AE. Clinical aspects of medication overuse headaches. Headache. 2014; 54: 211–217.